Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: Feasibility, compliance, and complications

International Journal of Gynecological Cancer

Volumn 22, Issue 6, 2012, Pages 1069-1074

  Benedetti Panici, Pierluigi ^a   Perniola, Giorgia ^a   Marchetti, Claudia ^a   Pernice, Milena ^a   Donfrancesco, Cristina ^a   Di Donato, Violante ^a   Tomao, Federica ^a   Palaia, Innocenza ^a   Graziano, Marialida ^a   Basile, Stefano ^b   Bellati, Filippo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Intraperitoneal chemotherapy; Recurrent ovarian cancer; Ultrasound guided direct puncture

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DISEASE SEVERITY; DRUG ADMINISTRATION; ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARIN CANCER; OVARY CANCER; PATIENT COMPLIANCE; PATIENT SAFETY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT OVARIAN CANCER; REVIEW; ULTRASOUND GUIDED DIRECT PUNCTURE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATIENT COMPLIANCE; PILOT PROJECTS; PROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84863627222     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31825736b2     Document Type: Review

References (15)

1. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl JMed. 1996;335:1950-1955.
2. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
3. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
4. Barakat RR, Almadrones L, Venkatraman ES, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage IIYIV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 1998;69:17-22.
5. Benedetti Panici P, Palaia I, Graziano M, et al. Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study. Oncology. 2010; 78:20-25.
6. Marth C, Walker JL, Barakat RR, et al. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer. 2007;109:645-649.
7. Naumann RW, Sukumvanich P, Edwards RP. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecol Oncol. 2009;114:37-41.
8. Black D, Levine DA, Nicoll L, et al. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol. 2008;109:39-42.
9. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003;90:637-643.
10. Davidson SA, Rubin SC, Markman M, et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol. 1991;41:101-106.
11. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27-32.
12. Lan C, Li Y, Liu J. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009;114:42-47.
13. Robinson WR, Beyer J. Factors affecting the completetion of intraperitoneal chemotherapy in women with ovarian cancer. Int J Gynecol Cancer. 2010;20:70-74.
14. Havrilesky LJ, Secord AA, Darcy KM, et al. Gynecologic Oncology Group. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:4144-4150.
15. Landrum LM, Gold MA, Moore KN, et al. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008;108:342-347.